DURECT Announces Plans for a New POSIDUR Clinical Trial By: Benzinga via Benzinga June 23, 2015 at 08:01 AM EDT DURECT Corporation (Nasdaq: DRRX) announced that, based on feedback from the FDA, it plans to conduct a new POSIDUR™ ... Read More >> Related Stocks: Durect Corp